Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.7% ...

This was the stock's fourth consecutive day of losses.

Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...

Shares of CRBP stock opened at $6.96 on Monday. The firm’s 50-day simple moving average is $9.32 and its 200-day simple moving average is $18.10. Corbus Pharmaceuticals has a 1-year low of $6.38 ...

Oppenheimer analyst Jeff Jones reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target ...

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.7% over the past four weeks, the stock looks well positioned for a trend ...

This was the stock's second consecutive day of losses.